Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-Resistant Staphylococcus aureus

The discovery of new classes of antibiotics is slow, and it is being greatly outpaced by the development of bacterial resistance. This disparity places us in an increasingly vulnerable position because we are running out of safe and effective therapeutic options to treat antibiotic-resistant infecti...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel) 2022-11, Vol.11 (11), p.1550
Main Authors: Yang, Junshu, Brown, Christopher, Noland, Wayland, Johnson, Timothy J., Ji, Yinduo
Format: Article
Language:English
Subjects:
Antibacterial activity
Antibacterial agents
Antibacterial materials
Antibiotic resistance
Antibiotics
antimicrobial agents
Apoptosis
Bacteria
Bacterial infections
Bactericidal activity
Chemical compounds
Cytotoxicity
Drug resistance
E coli
Gram-positive bacterial pathogen
Infections
Low concentrations
Mammalian cells
Methicillin
MRSA
Multidrug resistance
Mutation
Pathogens
Pharmacology
Public health
Staphylococcus aureus
Staphylococcus infections
Streptococcus infections
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery of new classes of antibiotics is slow, and it is being greatly outpaced by the development of bacterial resistance. This disparity places us in an increasingly vulnerable position because we are running out of safe and effective therapeutic options to treat antibiotic-resistant infections. This is exemplified by the emergence and persistence of hospital-acquired and community-associated methicillin-resistant S. aureus (MRSA), which has markedly narrowed our options for treating life-threatening staph infections. Thus, there is an urgent need to develop novel, potent, preventive, and therapeutic agents. In our current study, we performed a whole-cell screening assay of synthetic libraries for antibacterial activity and identified a novel molecule, MZ-01. MZ-01 exhibited potent bactericidal activity against Gram-positive bacterial pathogens, including MRSA, Streptococcus pyogenes, and Streptococcus pneumoniae, at low concentrations. MZ-01 killed and lysed both the late exponential phase of an S. aureus population and bacteria inside mammalian cells. Furthermore, MZ-01 exhibited low cytotoxicity. These results indicate that MZ-01 is a promising scaffold to guide the development of novel, potent antibacterial agents against multidrug-resistant Gram-positive bacterial pathogens such as MRSA.
ISSN:2079-6382
2079-6382
DOI:10.3390/antibiotics11111550